Adapting cutting edge technologies

The TriviumVet pipeline comprises innovative treatments for diseases where there are no specific veterinary approved drugs.

Our focus is on adapting cutting edge technology developed for human medicine to improve the accessibility for our pets.

Our therapeutic candidates are formulated for species specific suitability, tested for safety and efficacy and are then submitted to the FDA (Center for Veterinary Medicine) and the EMA European Medicines Agency (CVMP) for approval.